Evolus Inc Stock Performance
| EOLS Stock | USD 13.20 0.24 1.85% |
On a scale of 0 to 100, Evolus holds a performance score of 4. The firm shows a Beta (market volatility) of 0.56, which means possible diversification benefits within a given portfolio. As returns on the market increase, Evolus' returns are expected to increase less than the market. However, during the bear market, the loss of holding Evolus is expected to be smaller as well. Please check Evolus' semi variance, and the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Evolus' price patterns will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Evolus Inc are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively conflicting essential indicators, Evolus unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 62.8 M |
Evolus |
Evolus Relative Risk vs. Return Landscape
If you would invest 1,173 in Evolus Inc on December 17, 2024 and sell it today you would earn a total of 147.00 from holding Evolus Inc or generate 12.53% return on investment over 90 days. Evolus Inc is currently generating 0.2982% in daily expected returns and assumes 4.8215% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Evolus, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Evolus Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Evolus' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Evolus Inc, and traders can use it to determine the average amount a Evolus' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0619
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | EOLS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.82 actual daily | 42 58% of assets are more volatile |
Expected Return
| 0.3 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Evolus is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Evolus by adding it to a well-diversified portfolio.
Evolus Fundamentals Growth
Evolus Stock prices reflect investors' perceptions of the future prospects and financial health of Evolus, and Evolus fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Evolus Stock performance.
| Return On Equity | -8.62 | ||||
| Return On Asset | -0.0808 | ||||
| Profit Margin | (0.19) % | ||||
| Operating Margin | (0.01) % | ||||
| Current Valuation | 882.37 M | ||||
| Shares Outstanding | 63.59 M | ||||
| Price To Earning | (5.55) X | ||||
| Price To Book | 152.00 X | ||||
| Price To Sales | 3.15 X | ||||
| Revenue | 264.31 M | ||||
| EBITDA | (25 M) | ||||
| Cash And Equivalents | 84.48 M | ||||
| Cash Per Share | 1.51 X | ||||
| Total Debt | 8.47 M | ||||
| Debt To Equity | 1.59 % | ||||
| Book Value Per Share | 0.09 X | ||||
| Cash Flow From Operations | (18 M) | ||||
| Earnings Per Share | (0.81) X | ||||
| Total Asset | 232.57 M | ||||
| Retained Earnings | (609.4 M) | ||||
| Current Asset | 27.24 M | ||||
| Current Liabilities | 76.8 M | ||||
About Evolus Performance
Assessing Evolus' fundamental ratios provides investors with valuable insights into Evolus' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Evolus is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. The company was incorporated in 2012 and is headquartered in Newport Beach, California. Evolus operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 174 people.Things to note about Evolus Inc performance evaluation
Checking the ongoing alerts about Evolus for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Evolus Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Evolus Inc had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 264.31 M. Net Loss for the year was (50.42 M) with profit before overhead, payroll, taxes, and interest of 182.3 M. | |
| Evolus Inc currently holds about 84.48 M in cash with (18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.51. | |
| Over 83.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Evolus' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Evolus' stock is overvalued or undervalued compared to its peers.
- Examining Evolus' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Evolus' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Evolus' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Evolus' stock. These opinions can provide insight into Evolus' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Evolus Stock Analysis
When running Evolus' price analysis, check to measure Evolus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evolus is operating at the current time. Most of Evolus' value examination focuses on studying past and present price action to predict the probability of Evolus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evolus' price. Additionally, you may evaluate how the addition of Evolus to your portfolios can decrease your overall portfolio volatility.